Market Cap 15.80B
Revenue (ttm) 20.92B
Net Income (ttm) 582.08M
EPS (ttm) N/A
PE Ratio 14.48
Forward PE 12.60
Profit Margin 2.78%
Debt to Equity Ratio 0.51
Volume 188,100
Avg Vol 321,408
Day's Range N/A - N/A
Shares Out 586.83M
Stochastic %K 72%
Beta 0.92
Analysts Sell
Price Target $27.74

Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 49 6172 609 0
Address:
Else-Kröner-Strasse 1, Bad Homburg, Germany
ZacksResearch
ZacksResearch Oct. 24 at 6:41 PM
$FMS up 18.9% YTD, outperforming the industry’s decline of 1.9% and the S&P 500's 14.9% drop — why is it outperforming the market? 🔍 🌍 Strong global footprint with strategic acquisitions and partnerships 💰 NxStage deal projected to add $80$100M in savings 📈 Solid earnings history, average surprise of 7.6% Discover what’s driving FMS’s growth here 👉 https://www.zacks.com/stock/news/2776732/reasons-to-hold-fresenius-medical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2776732-body-17652&ADID=SYND_STOCKTWITS_TWEET_2_2776732_BODY_17652
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 5:41 PM
$FMS stays on investors’ radar — but is it worth holding right now? 💊 Acquisitions, partnerships, and a strong global footprint are driving growth, even as rising costs pressure near-term results. Full hold-case breakdown here 👉 https://www.zacks.com/stock/news/2776732/reasons-to-hold-fresenius-medical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2776732-teaser-17632&ADID=SYND_STOCKTWITS_TWEET_2_2776732_TEASER_17632
0 · Reply
Noname2022
Noname2022 Oct. 24 at 10:06 AM
$FMS Still counting all of the tens of millions made from using defencath in Q3…
0 · Reply
Noname2022
Noname2022 Oct. 22 at 6:22 PM
$CRMD $FMS 85 Million in DefenCath Q3 What I Think Is Happening
3 · Reply
wolverine
wolverine Oct. 22 at 3:52 PM
$CRMD $70 million EBITDA Q3, is the fear this is a large one time order in Q3? Hard to believe $FMS ordered all in one quarter and not just ramping up? So potentially close to $300 million EBITDA for 2026 but the market cap is only $875 million? Compare other drug/biotech companies and their multiple? Just crazy this price!!!
1 · Reply
Noname2022
Noname2022 Oct. 22 at 2:46 PM
$CRMD $DVA $FMS While every other provider protects patients, DaVita chooses to ignore DefenCath, the therapy proven to prevent deadly infections and costly hospitalizations. This isn’t caution or strategy, it’s negligence dressed as cost control. The market sees it, regulators see it, and patients feel it. When the fallout hits, it won’t be measured in dollars, it will be measured in lives.
5 · Reply
Noname2022
Noname2022 Oct. 21 at 12:29 PM
$CRMD $FMS People love to hate on analysts and their price targets. What most don’t see are the upside targets built into their models that assume everything goes right. For CorMedix, those could be $28$30+ if that’s how things play out. Based on the latest PR, do you think everything’s going right?
2 · Reply
Noname2022
Noname2022 Oct. 20 at 11:24 PM
$CRMD $FMS Thanks Pete!
0 · Reply
Noname2022
Noname2022 Oct. 18 at 6:05 PM
3 · Reply
Goosey71
Goosey71 Oct. 16 at 7:26 PM
$FMS Leuvocorin sales up? Only ASD answers please
0 · Reply
Latest News on FMS
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 11:23 AM EDT - 2 months ago

Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript


5 Stocks To Ride The German Market Rally

Jun 16, 2025, 3:06 PM EDT - 4 months ago

5 Stocks To Ride The German Market Rally

BNTX SAP


Fresenius Medical Care tops market expectations in 1st quarter

May 6, 2025, 1:04 AM EDT - 6 months ago

Fresenius Medical Care tops market expectations in 1st quarter


Fresenius Medical Care's stock falls on Fresenius' stake sale

Mar 4, 2025, 3:57 AM EST - 8 months ago

Fresenius Medical Care's stock falls on Fresenius' stake sale


Fresenius Medical Care: A 'Buy' Going Into 2025

Jan 31, 2025, 6:20 AM EST - 9 months ago

Fresenius Medical Care: A 'Buy' Going Into 2025


Fresenius Medical Care returns to Dax 40 Index

Dec 20, 2024, 11:23 AM EST - 11 months ago

Fresenius Medical Care returns to Dax 40 Index


Fresenius Medical Care: Let's Look At The Upside

Oct 4, 2024, 4:04 PM EDT - 1 year ago

Fresenius Medical Care: Let's Look At The Upside


US FTC probing DaVita, Fresenius Medical, Politico reports

Jul 13, 2024, 9:16 AM EDT - 1 year ago

US FTC probing DaVita, Fresenius Medical, Politico reports

DVA


Fresenius Medical Care: Significant Upside Remains

Jun 25, 2024, 6:15 AM EDT - 1 year ago

Fresenius Medical Care: Significant Upside Remains


ZacksResearch
ZacksResearch Oct. 24 at 6:41 PM
$FMS up 18.9% YTD, outperforming the industry’s decline of 1.9% and the S&P 500's 14.9% drop — why is it outperforming the market? 🔍 🌍 Strong global footprint with strategic acquisitions and partnerships 💰 NxStage deal projected to add $80$100M in savings 📈 Solid earnings history, average surprise of 7.6% Discover what’s driving FMS’s growth here 👉 https://www.zacks.com/stock/news/2776732/reasons-to-hold-fresenius-medical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2776732-body-17652&ADID=SYND_STOCKTWITS_TWEET_2_2776732_BODY_17652
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 5:41 PM
$FMS stays on investors’ radar — but is it worth holding right now? 💊 Acquisitions, partnerships, and a strong global footprint are driving growth, even as rising costs pressure near-term results. Full hold-case breakdown here 👉 https://www.zacks.com/stock/news/2776732/reasons-to-hold-fresenius-medical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2776732-teaser-17632&ADID=SYND_STOCKTWITS_TWEET_2_2776732_TEASER_17632
0 · Reply
Noname2022
Noname2022 Oct. 24 at 10:06 AM
$FMS Still counting all of the tens of millions made from using defencath in Q3…
0 · Reply
Noname2022
Noname2022 Oct. 22 at 6:22 PM
$CRMD $FMS 85 Million in DefenCath Q3 What I Think Is Happening
3 · Reply
wolverine
wolverine Oct. 22 at 3:52 PM
$CRMD $70 million EBITDA Q3, is the fear this is a large one time order in Q3? Hard to believe $FMS ordered all in one quarter and not just ramping up? So potentially close to $300 million EBITDA for 2026 but the market cap is only $875 million? Compare other drug/biotech companies and their multiple? Just crazy this price!!!
1 · Reply
Noname2022
Noname2022 Oct. 22 at 2:46 PM
$CRMD $DVA $FMS While every other provider protects patients, DaVita chooses to ignore DefenCath, the therapy proven to prevent deadly infections and costly hospitalizations. This isn’t caution or strategy, it’s negligence dressed as cost control. The market sees it, regulators see it, and patients feel it. When the fallout hits, it won’t be measured in dollars, it will be measured in lives.
5 · Reply
Noname2022
Noname2022 Oct. 21 at 12:29 PM
$CRMD $FMS People love to hate on analysts and their price targets. What most don’t see are the upside targets built into their models that assume everything goes right. For CorMedix, those could be $28$30+ if that’s how things play out. Based on the latest PR, do you think everything’s going right?
2 · Reply
Noname2022
Noname2022 Oct. 20 at 11:24 PM
$CRMD $FMS Thanks Pete!
0 · Reply
Noname2022
Noname2022 Oct. 18 at 6:05 PM
3 · Reply
Goosey71
Goosey71 Oct. 16 at 7:26 PM
$FMS Leuvocorin sales up? Only ASD answers please
0 · Reply
Noname2022
Noname2022 Oct. 16 at 12:28 PM
1 · Reply
Estimize
Estimize Oct. 16 at 11:03 AM
Wall St is expecting 0.57 EPS for $FMS Q3 [Reporting 11/04 BMO] http://www.estimize.com/intro/fms?chart=historical&metric_name=eps&utm_cont
0 · Reply
Noname2022
Noname2022 Oct. 15 at 12:40 PM
$CRMD $FMS Watching closely for a potential DefenCath real-world evidence (RWE) abstract drop at ASN or IDWeek. With embargoes lifting Friday, odds favor a CorMedix PR Fri AM – Mon AM if data are ready. Hope springs eternal.
0 · Reply
Noname2022
Noname2022 Oct. 14 at 8:32 PM
3 · Reply
Noname2022
Noname2022 Oct. 14 at 7:58 AM
$CRMD $FMS Oct 17 ASN drop day. If CorMedix’s RWE shows up, that’s the quiet spark before the street catches on. Think infection cuts, cost savings, real-world validation right as the nephrology crowd’s paying attention.
1 · Reply
Goosey71
Goosey71 Oct. 13 at 7:14 PM
$FMS Been watching a few FB groups to see whether Leucovorin is making a difference in Autism and it seems to be fantastic for non-verbal kids. FMS are a supplier. Look to this being meaningful in quarterly earnings going forward.
0 · Reply
wolfofwestloop
wolfofwestloop Oct. 13 at 2:53 AM
$AKBA $CRMD $DVA $FMS call and email your Senators and voice your support! It will take 2 minutes or less for each call...
0 · Reply
Noname2022
Noname2022 Oct. 13 at 12:16 AM
1 · Reply
Noname2022
Noname2022 Oct. 12 at 8:59 PM
$CRMD $AKBA $FMS $DVA https://www.fiercehealthcare.com/providers/op-ed-medicare-payment-reform-needed-support-innovation-kidney-care
3 · Reply
BrennadPurdysw
BrennadPurdysw Oct. 12 at 5:45 PM
CVKD Exciting news: Cadrenal Therapeutics Company Webcast @ Lytham Partners Fall 2025 Investor Conference. Watch live here: https://youtu.be/NfPbBjgeIbg?si=2xPvJ2_YJQjHipGa $ETH.X $ACON $FMS $BTC.X $ENTO
0 · Reply
Noname2022
Noname2022 Oct. 12 at 5:27 PM
$CRMD $AKBA $FMS $DVA Nov 1 CMS ESRD Rule Updates likely delayed In 2013, after a 16-day government shutdown (Oct 1–17), CMS released the CY 2014 ESRD PPS Final Rule on Dec 2—about 31 days later than the usual Nov 1 deadline, proving shutdowns can delay but not derail Medicare payment rules.
1 · Reply
Noname2022
Noname2022 Oct. 12 at 5:13 PM
$CRMD $AKBA $FMS $DVA House version of S. 2730 – The Kidney Care Access Protection Act expected (after gov’t shutdown of course) https://www.dialysispatients.org/news/support-s-2730-the-kidney-care-access-protection-act/
0 · Reply